心脏再同步治疗对左心室大小和功能在慢性心力衰竭中的影响
Martin G St John Sutton1, Ted Plappert, William T Abraham
1Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, 19104, USA. suttonm@mail.med.upenn.edu
Circulation
|April 2, 2003
概括
心脏再同步疗法 (CRT) 通过减少左心室大小和改善心力衰竭患者的射出分数来改善心脏功能. 这种疗法促进逆向重塑,并提高整体心脏性能.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭管理的管理
- 医疗器械 医疗器械
背景情况:
- 心脏再同步疗法 (CRT) 是一种被公认的治疗方法,用于治疗中度至重度心性心力衰竭与心室失同.
- 这项研究调查了CRT对左心室 (LV) 维度和功能的影响.
研究的目的:
- 评估CRT是否导致LV大小和功能的改善.
- 为了评估CRT和反向LV改造之间的关联.
主要方法:
- 来自MIRACLE试验的323名患者在基线和治疗后6个月接受了多普勒心声图.
- 患者被随机分配到CRT在 (172) 或CRT离 (151) 组.
- 关键测量包括LV体积,射出分数,LV质量和腹反.
主要成果:
- 通过CRT显著降低了LV终端-透析和终端-收缩体积,LV质量和 mitra反.
- 射出分数和心肌性能指数在CRT时显著改善.
- 在非缺血性心力衰竭患者中,改善更为明显.
结论:
- 在接受最佳医疗治疗的心力衰竭患者中,CRT与反向LV重塑和改善心力衰竭和心力衰竭功能有关.
- 通过CRT诱导的LV重塑可能有助于症状益处,并可能改善长期生存率.
- 对于部分心力衰竭患者来说,CRT提供了显著的治疗优势.
更多相关视频
相关概念视频
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


